- Home
- ABSI vs GLSI Comparison
ABSI vs GLSI Comparison
Compare ABSI & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABSI | GLSI |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.9M | 372.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ABSI | GLSI |
|---|---|---|
| Price | $3.06 | $26.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $7.47 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 4.3M | 133.7K |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.64 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,534,000.00 | N/A |
| Revenue This Year | $631.04 | N/A |
| Revenue Next Year | $75.73 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $7.78 |
| 52 Week High | $5.23 | $34.10 |
Technical Indicators
Market Signals| Indicator | ABSI | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 56.76 |
| Support Level | $2.45 | $23.32 |
| Resistance Level | $3.27 | $30.02 |
| Average True Range (ATR) | 0.21 | 1.76 |
| MACD | 0.01 | 0.34 |
| Stochastic Oscillator | 62.61 | 96.71 |
Price Performance
Historical ComparisonAbout ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.